Women diagnosed with non-small cell lung cancers (NSCLC) live longer than their male counterparts, according to results of a SWOG study presented by Loyola Medicine researcher Kathy Albain, MD, at the International Association ...
Oct 1, 2018
0
47
A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented ...
Dec 7, 2017
0
1
With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online ...
Oct 26, 2017
0
1
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data ...
Apr 3, 2017
0
1
The genetic mutations underlying treatment resistance in non-small cell lung cancer (NSCLC) are more complex and dynamic than previously thought. Analysis of 355 biopsied tumors from patients who acquired resistance to EGFR ...
Mar 16, 2017
0
3
Analysis of the largest American cancer database indicates that racial disparities persist in the treatment and outcomes of patients diagnosed with stage I non-small cell lung cancer (NSCLC). Despite increased availability ...
Mar 16, 2017
0
0
Black residents of highly segregated neighborhoods were less likely to receive surgery for early-stage non-small cell lung cancer (NSCLC) than their peers in less-segregated neighborhoods, according to a study published in ...
May 2, 2016
0
10
Patients younger than 50 diagnosed with non-small-cell lung cancer (NSCLC) had a higher likelihood of having a targetable genomic alteration for which therapies exist, according to an article published online by JAMA Oncology.
Dec 17, 2015
0
0
(HealthDay)—The U.S. Food and Drug Administration has approved Opdivo (nivolumab) to treat patients with advanced non-small-cell lung cancer (NSCLC) whose disease progressed despite platinum-based chemotherapy.
Oct 12, 2015
0
16
Tobacco smoke is known to be the main risk factor for non-small cell lung cancer (NSCLC), although non-smokers can get it too. The incidence among non-smokers is increasing in many countries. Now a group of Portuguese researchers ...
Sep 27, 2015
0
22
